Sanofi SA

Sign up to access all our data and the evidence and analysis underlying our overall scores. Once you've created an account, we'll get in touch with further details:

Sign Up

Direct Lobbying Transparency

Overall Assessment	Comment	Score
Moderate	Sanofi discloses the precise law it engaged with in France—Grenelle II Law Articles 75 and 225 mandating scope 1+2 GHG emissions reporting—and details that it provided feedback directly to the DGEC (Direction Générale de l’Énergie et du Climat), requesting a single consolidated Group-wide report instead of separate filings by entity. It complements this with clear policy end goals, calling for “regulatory and financial frameworks that recognize and reward our efforts on reducing our environmental impact” with “flexible and predictable” targets and incentives for post-approval innovations. In the Spanish healthcare sector, Sanofi advocates for environmental criteria in vaccine procurement, aiming to cut vaccine waste by 800,000 units annually, reduce packaging emissions by nearly 1,500 tons per year, and promote a “green public procurement” approach. Outside of these initiatives, Sanofi does not name additional specific climate laws and provides limited information on other engagement mechanisms or targeted policymakers.	2

Lobbying Governance

Overall Assessment	Comment	Score
Limited	Sanofi SA states that it “has a public commitment or position statement to conduct its engagement activities in line with the goals of the Paris Agreement.” However, the company does not disclose any formal framework or procedure for monitoring or managing how its direct or indirect lobbying activities align with that commitment, nor does it identify any individual or governance body responsible for overseeing its lobbying alignment with climate goals. We found no evidence of a review process for climate lobbying or any mechanisms to ensure ongoing alignment beyond this public statement.	1